GlassScriptPhysician profile
Hamed Mataria
NPI 1285845818
$14,363.31
in general payments reported to CMS, 2019-2025
29 companies · $1,375 in 2025
The $1,375 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $242 · 2021: $378 · 2022: $891 · 2023: $822 · 2024: $10K · 2025: $1,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,100 · Food and Beverage: $3,154 · Travel and Lodging: $2,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,099.99 |
| Food and Beverage | $3,154.07 |
| Travel and Lodging | $2,034.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,181.41 | 2024 | |
| Glaxosmithkline, LLC. | $1,614.98 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $549.34 | 2019-2025 | Breztri, Tezspire, Fasenra |
| Jazz Pharmaceuticals INC. | $445.43 | 2019-2024 | |
| Genzyme Corporation | $345.85 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $271.02 | 2019-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.81 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Pulmonx Corporation | $227.67 | 2024-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Insmed, INC. | $198.04 | 2019-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $194.92 | 2020-2025 | Dupixent |
| Grifols USA, LLC | $118.80 | 2022-2025 | Prolastin-C Liquid |
| Philips North America LLC | $97.01 | 2019-2025 | Vest Therapy Und |
| Electromed, INC. | $95.01 | 2022-2025 | Smartvest |
| Mylan Specialty L.P. | $88.21 | 2019-2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $85.28 | 2023 | Glassia, Hyqvia, Ninlaro |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $81.83 | 2022-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $78.72 | 2024-2025 | Lumryz |
| Amgen INC. | $77.93 | 2024-2025 | Tezspire |
| United Therapeutics Corporation | $72.93 | 2019-2024 | Tyvaso |
| Merck Sharp & Dohme LLC | $70.96 | 2022-2023 | Zerbaxa, Dificid |
| Baxter Healthcare | $53.04 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Genentech USA, INC. | $30.35 | 2022-2025 | Xolair |
| Circassia INC. | $27.49 | 2019 | |
| Advanced Respiratory, INC | $26.98 | 2021 | |
| Ani Pharmaceuticals, INC. | $24.99 | 2023 | Purified Cortrophin Gel |
| Mayne Pharma Commercial LLC | $16.83 | 2019 | |
| Chiesi USA, INC. | $16.09 | 2019 | |
| Pfizer INC. | $15.39 | 2025 | |
| Paratek Pharmaceuticals, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamed Mataria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.